Last reviewed · How we verify
Sublingual Tizanidine HCl
Sublingual Tizanidine HCl is a Small molecule drug developed by Teva GTC. It is currently in Phase 1 development.
At a glance
| Generic name | Sublingual Tizanidine HCl |
|---|---|
| Sponsor | Teva GTC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- One Year Extension Study To Protocol C2/5/TZ:MS-05 (PHASE1, PHASE2)
- Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity (PHASE1, PHASE2)
- Pilot, Proof-of-Concept Study of Sublingual Tizanidine in Children With Chronic Traumatic Brain Injury (TBI) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sublingual Tizanidine HCl CI brief — competitive landscape report
- Sublingual Tizanidine HCl updates RSS · CI watch RSS
- Teva GTC portfolio CI
Frequently asked questions about Sublingual Tizanidine HCl
What is Sublingual Tizanidine HCl?
Sublingual Tizanidine HCl is a Small molecule drug developed by Teva GTC.
Who makes Sublingual Tizanidine HCl?
Sublingual Tizanidine HCl is developed by Teva GTC (see full Teva GTC pipeline at /company/teva-gtc).
What development phase is Sublingual Tizanidine HCl in?
Sublingual Tizanidine HCl is in Phase 1.
Related
- Manufacturer: Teva GTC — full pipeline
- Compare: Sublingual Tizanidine HCl vs similar drugs
- Pricing: Sublingual Tizanidine HCl cost, discount & access